1. Home
  2. PMM vs FDMT Comparison

PMM vs FDMT Comparison

Compare PMM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

HOLD

Current Price

$6.17

Market Cap

276.3M

Sector

Finance

ML Signal

HOLD

Logo 4D Molecular Therapeutics Inc.

FDMT

4D Molecular Therapeutics Inc.

HOLD

Current Price

$8.61

Market Cap

513.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMM
FDMT
Founded
1989
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.3M
513.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PMM
FDMT
Price
$6.17
$8.61
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$33.50
AVG Volume (30 Days)
88.5K
609.3K
Earning Date
01-01-0001
03-18-2026
Dividend Yield
4.68%
N/A
EPS Growth
N/A
18.79
EPS
0.23
N/A
Revenue
N/A
$85,209,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.28
P/E Ratio
$27.33
N/A
Revenue Growth
N/A
230194.60
52 Week Low
$5.66
$2.24
52 Week High
$6.52
$12.34

Technical Indicators

Market Signals
Indicator
PMM
FDMT
Relative Strength Index (RSI) 34.20 47.60
Support Level $6.06 $8.15
Resistance Level $6.19 $8.80
Average True Range (ATR) 0.06 0.56
MACD -0.02 -0.02
Stochastic Oscillator 0.00 27.43

Price Performance

Historical Comparison
PMM
FDMT

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: